News
LivaNova to Announce First-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis (TB) infection more than
QIAGEN erreicht mit 100 Millionen durchgeführten QuantiFERON-Tests einen Meilenstein im Kampf gegen die Tuberkulose
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute anlässlich des Welttuberkulosetages bekannt, dass sein QuantiFERON-Bluttest seit seiner Markteinführung mehr als 100 Millionen Mal
DGAP-News: RHÖN-KLINIKUM AG schließt Geschäftsjahr 2021 erfolgreich ab
DGAP-News: RHÖN-KLINIKUM AG looks back on successful financial year 2021
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study evaluating the safety and efficacy of Tumor Treating Fields
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006149/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
DGAP-News: MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
DGAP-News: MorphoSys und Incyte geben vorläufige Swissmedic-Zulassung von Minjuvi(R) (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von erwachsenen Patienten mit R/R DLBCL bekannt
AMN Healthcare Named to Barron’s 100 Most Sustainable Companies
AMN Healthcare, the nation’s leader in total talent solutions for healthcare organizations, has been named to America’s 100 Most Sustainable Companies by Barron’s magazine.
“The AMN team and our
DGAP-News: Evotec receives € 3 m milestone payment for Bayer starting Phase II clinical development of DNP programme
DGAP-News: Evotec erhält 3 Mio. €-Meilenstein für Bayers Start einer klinischen Phase-II-Studie mit DNP-Programm
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung
DGAP-News: MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Southcoast Behavioral Health Expands Services and Capacity
Southcoast Behavioral Health today reinforced its strong commitment to the communities it serves through the addition of a dedicated child and adolescent behavioral health program, expanding the
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) stuft Monjuvi(R) (Tafasitamab-cxix) in seinen Leitlinien als bevorzugte Behandlungsmethode für B-Zell-Lymphome ein
DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Premier Inc. Named One of the 2022 World’s Most Ethical Companies® by Ethisphere® for 15th Consecutive Year
Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study, “A P
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended
ICON plc to Webcast Analyst Day Meeting
ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will provide a live webcast of its Analyst Day meeting which will take
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 17. März 2022 zu den Ergebnissen des Geschäftsjahres 2021
DGAP-News: Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG meldet nicht zahlungswirksame Wertminderung des Geschäfts- oder Firmenwertes von 231 Mio. € nach F&E Konsolidierung; entsprechende Erhöhung des operativen Konzernaufwands in 2021